1. A 48-week update of a multicentre real-life experience of dupilumab in adult patients with moderate-to-severe atopic dermatitis. (17th February 2022) Authors: Fargnoli, M. C.; Esposito, M.; Ferrucci, S.; Girolomoni, G.; Offidani, A.; Patrizi, A.; Peris, K.; Costanzo, A.; Malara, G.; Pellacani, G.; Romanelli, M.; Amerio, P.; Cristaudo, A.; Flori, M. L.; Motolese, A.; Betto, P.; Patruno, C.; Pigatto, P.; Peccianti, C.; Stinco, G. Journal: Journal of dermatological treatment Issue: Volume 33:Number 2(2022) Page Start: 1146 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Real-life experience on effectiveness and safety of dupilumab in adult patients with moderate-to-severe atopic dermatitis. (4th July 2021) Authors: Fargnoli, M. C.; Esposito, M.; Ferrucci, S.; Girolomoni, G.; Offidani, A.; Patrizi, A.; Peris, K.; Costanzo, A.; Malara, G.; Pellacani, G.; Romanelli, M.; Amerio, P.; Cristaudo, A.; Flori, M. L.; Motolese, A.; Betto, P.; Patruno, C.; Pigatto, P.; Sirna, R.; Stinco, G. Journal: Journal of dermatological treatment Issue: Volume 32:Number 5(2021) Page Start: 507 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗